社论:艾滋病新药:现状如何?

IF 4.5 3区 医学 Q2 IMMUNOLOGY
Charles W Flexner, Angela Kashuba
{"title":"社论:艾滋病新药:现状如何?","authors":"Charles W Flexner, Angela Kashuba","doi":"10.1097/COH.0000000000000710","DOIUrl":null,"url":null,"abstract":"The WHO estimates that by the beginning of 2021, 27.5 million adults and children were receiving antiretroviral treatment [1]. Many of these individuals are taking a coformulated generic combination of dolutegravir with tenofovir disoproxil fumarate (TDF) and lamivudine (TLD), a daily oral combination that could be thought of as the ‘universal antiretroviral regimen [2]’. In the face of numbers like this, one could easily wonder if there is even a need for new treatments for HIV. Although it has been more than 3 years since this journal reviewed the topic of ‘New Drugs for HIV’, the Table of","PeriodicalId":10949,"journal":{"name":"Current Opinion in HIV and AIDS","volume":"17 1","pages":"1-3"},"PeriodicalIF":4.5000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Editorial: New drugs for HIV: quo vadis?\",\"authors\":\"Charles W Flexner, Angela Kashuba\",\"doi\":\"10.1097/COH.0000000000000710\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The WHO estimates that by the beginning of 2021, 27.5 million adults and children were receiving antiretroviral treatment [1]. Many of these individuals are taking a coformulated generic combination of dolutegravir with tenofovir disoproxil fumarate (TDF) and lamivudine (TLD), a daily oral combination that could be thought of as the ‘universal antiretroviral regimen [2]’. In the face of numbers like this, one could easily wonder if there is even a need for new treatments for HIV. Although it has been more than 3 years since this journal reviewed the topic of ‘New Drugs for HIV’, the Table of\",\"PeriodicalId\":10949,\"journal\":{\"name\":\"Current Opinion in HIV and AIDS\",\"volume\":\"17 1\",\"pages\":\"1-3\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in HIV and AIDS\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/COH.0000000000000710\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in HIV and AIDS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/COH.0000000000000710","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Editorial: New drugs for HIV: quo vadis?
The WHO estimates that by the beginning of 2021, 27.5 million adults and children were receiving antiretroviral treatment [1]. Many of these individuals are taking a coformulated generic combination of dolutegravir with tenofovir disoproxil fumarate (TDF) and lamivudine (TLD), a daily oral combination that could be thought of as the ‘universal antiretroviral regimen [2]’. In the face of numbers like this, one could easily wonder if there is even a need for new treatments for HIV. Although it has been more than 3 years since this journal reviewed the topic of ‘New Drugs for HIV’, the Table of
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Opinion in HIV and AIDS
Current Opinion in HIV and AIDS IMMUNOLOGY-INFECTIOUS DISEASES
CiteScore
7.40
自引率
7.30%
发文量
115
审稿时长
6-12 weeks
期刊介绍: Published bimonthly and offering a unique and wide ranging perspective on the key developments in the field, each issue of Current Opinion in HIV and AIDS features hand-picked review articles from our team of expert editors. With six disciplines published across the year – including HIV and ageing, a HIV vaccine, and epidemiology – every issue also contains annotated reference detailing the merits of the most important papers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信